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Impurity Occurrence and Removal in Crystalline 
Products from Process Reactions 
Humphrey A. Moynihan* and Danielle E. Horgan 
Department of Chemistry / Analytical and Biological Chemistry Research Facility / Synthesis 
and Solid-state Pharmaceutical Centre, University College Cork, Cork, Ireland. 
ABSTRACT The behaviour of impurities when subjected to crystallisations, and related 
processes such as recrystallisation and reslurrying, has been reviewed with a particular focus 
on the years 2000 to 2015, but also including significant cases from outside that period. Small 
molecule pharmaceuticals and similar small organic molecules are included but not 
biomolecules, inorganics or minerals. Phase impurities are only covered when a phase 
transformation is involved with the management of an impurity. Introductory examples 
illustrating some general features of crystallisation as a method of purification are presented, 
as well as approaches to quantifying the effectiveness of purification. The review classifies 
cases based on the behaviour of the specific impurities covered. The classes of behaviour 
observed are removal by washing, recrystallisation or reslurrying (Class 1), impurities not 
being removed by these operations (Class 2), and impurities which are removed in conjunction 
with a phase transformation (Class 3). Examples of each of these types of behaviour are 
presented, with many processes producing impurities which fall into more than one of these 
classes.  Studies on the inclusion of extraneous molecules into crystalline materials are also 
covered. These particularly include incorporation of compounds as solid solutions, but also 
eutectic formation and inclusion at surfaces during crystal growth. The relationship between 
types of impurities and behaviour during processing is also examined. 
KEYWORDS Pharmaceuticals, impurities, crystallisation, solid solutions 
1. Introduction 
Generation of impurities during process chemistry, and the retention or otherwise of these 
during crystallisation and subsequent processing, is part of the reality of manufacturing 
pharmaceuticals and similar fine chemicals.1,2 FDA guidelines3-6  designate organics, 
inorganics and residual solvents as likelys impurities, and notes that organic impurities can 
arise during manufacturing or storage from starting materials, by-products, intermediates, 
degradation products, reagents, solvents, ligands, catalysts, stereoisomers and filter aids. 
Actual or potential impurities can arise during synthesis, purification and storage, and these 
must be noted and listed in the specification for any new drug substance. Of particular 
concern are possible genotoxic impurities such as alkyl halides or sulfonates.7,8 Organic 
impurities with a close structural similarity to the pharmaceutical entity are referred to as 
related substances.9  
Crystallisation is probably the most important method of product isolation and purification in 
pharmaceutical manufacturing. Hence, the presence of impurities in the crystallisation 
medium or in the crystal product is clearly a significant issue which may affect the 
specification compliance of the batch. Any impurities present must be known, quantified and 
shown to be below specified limits. It is widely appreciated that impurities in the 
crystallisation medium can affect crystal nucleation and growth rates, crystal phase 
occurrence including polymorphism or solvate formation, and crystal morphology including 
habit and crystal size distribution.10-16 The behaviour of impurities when subjected to 
crystallisations has been less explicitly studied, despite the critical role crystallisations play in 
impurity management. This review examines literature reports on the impact of 
crystallisations, and related processes such as recrystallisation and reslurrying, on the levels 
of specific impurities. The review covers the years 2000 to 2015 inclusive plus some 
significant earlier or more recent cases. The focus is on 'small molecule' pharmaceuticals and 
other drug-like small molecules, especially with regard to cases in which impurities arise 
from specific process chemistry. The scope of the review excludes proteins and other 
biomolecules, as well as minerals and bulk inorganics. Also excluded are phase impurities 
such as crystal polymorphs, solvates or hydrates, except in cases where phase transformations 
have been associated with control of specific molecular impurities. An overview of the 
behaviour of impurities when subjected to solid state processes such as recrystallisation or 
reslurrying should highlight patterns which can assist in designing a general scheme for 
troubleshooting impurities in solids and supporting rational process design.  
 
1.1 Crystallisation as a method of purification 
The success of crystallisation from solution as a method of purification lies in the selectivity 
of the processes of crystal nucleation and growth for the components of the crystal lattice, 
while other components present in the system, i.e. impurities, selectively remain in the 
mother liquor. This contrasts with, for example, spray drying, in which the solvent is fully 
removed to leave the solutes in particle form with no selection between differing components. 
The relative quantities of crystallising compound and impurities present in solution and the 
yield of the crystallisation are key factors in achieving successful purification. For example, 
in the crystallisation of ZD0947 1, the enantiomer 2 was the significant impurity (Figure 1). 
Crystallisations of compound 1 from acetonitrile were found to correspond closely to ideal 
behaviour characterised by the van't Hoff equation, giving a 90% yield upon cooling from 77 
to 5 °C. The input material needed to be of sufficient enantiopurity such that conditions for 
the crystallisation of racemic crystals did not occur. That required consideration of the yield 
of crystallised compound and the composition of the remaining solutes, such that the latter 
remained below the solution eutectic composition for formation of the crystalline racemic 
compound.17  
 
Figure 1. ZD0947 and Enantiomer 
 
A similar point is illustrated by the example of maleic acid 3 (Figure 2), in which fumaric 
acid 4 can occur as an impurity (Figure 2). The water solubility of fumaric acid is 
considerably lower than that of maleic acid (0.8 g/100 g and 91.2 g/100 g, respectively, at 30 
°C), such that the presence of undissolved fumaric acid impurity can lead to significant 
underestimation of the solubility of maleic acid.18 The eutectic for this system at 30 °C is at 
ca. 99.2% maleic acid : 0.8% fumaric acid, and the impurity, fumaric acid, is the less soluble 
compound. Hence, formation of solid impurity can occur if the impurity concentration of the 
input material is greater than the eutectic composition. Similarly, in the crystallisation of L-
isoleucine 5 (Figure 2), separate crystals of the impurities L-leucine 6 and L-valine 7 (Figure 
2) could form as a physical mixture with L-isoleucine crystals, if the impurity level was 
sufficiently high.19 For example, solutions containing between 5 to 10 mol L-Leu 6 per 100 
mol L-isoleucine 5 gave crystals with a mixture of needle-like and hexagonal habits, with a 
greater proportion of the crystals of hexagonal habit being observed with greater quantities of 
L-leucine impurity. High quantities of L-valine impurity gave samples containing 
agglomerates that consisted of well formed needles of L-isoleucine around which smaller 
crystals were present, believed to be of L-valine. 
 
Figure 2. Structures of Maleic Acid, Fumaric Acid, L-Isoleucine, L-Leucine and L-Valine 
 
1.2 Quantification of purification 
Workers have sought to quantify the level of impurity reduction in crystallisations. For 
example, impurity levels of dirithromycin 8 (Figure 3) following recrystallisation from 
acetone/water was plotted as a function of impurities in the technical material, showing a 
reasonable correlation for both overall impurities and dirithromycin B impurity 9 
specifically.20 
 
Figure 3. Dirithromycin and Dirithromycin B 
 
Purge factors for impurities have also been developed. These attempt to quantify the ease of 
removal of impurities during process development in general, rather than specifically by 
crystallisation.21, 22 In the purge factor approach, assessment of potential carry-over of 
impurities, especially genotoxic impurities, is based on factors such as reactivity, solubility, 
volatility, ionisability, and additional physical processes which may be involved, such as 
chromatography. Solubility relates to solubility in the solvent system used during isolation, in 
general by crystallisation. A score is assigned based on the physicochemical properties of the 
impurity relative to the process conditions. These are multiplied together to give the purge 
factor. For solubility, which is the most important of these factors relating to carry-over of 
impurities in crystallisation, an impurity which is freely soluble in the solvent system is 
assigned a value of 10, a moderately soluble impurity is assigned 3, a sparingly soluble 
impurity assigned 1. If the impurity in question is highly soluble it will remain within the 
mother liquors and be purged from the crystallized product, and hence have a high purge 
factor. For example, in the formation of AZD9056 11 by reductive amination followed by 
isolation by hydrochloride salt formation, a chloride by-product 12 occurs as an impurity 
(Scheme 1). The calculated purge factor for this impurity based on the aforementioned 
principles was 3, indicating that the process had limited capacity to remove the impurity and 
that the extent of its formation needed to be controlled. In this case, the experimental purge 
factor was found to be more favourable. In the same process, isopropyl chloride was also 
formed by degradation of the solvent, however, the calculated purge factor for this was 10, 
based on high solubility and volatility, predicting that isopropyl chloride should be 
effectively removed.21, 22 
Scheme 1. Final Steps in a Route to AZD9056 
  
A further example of the use of purge factors concerned the synthesis of an N-methylamide 
14 as an intermediate in a route to hepatitis C virus treatment MK-8876 17 (Scheme 2). 
Compound 14 was obtained by coupling using EDC with direct crystallisation of the product. 
The purge factor for EDC was 10. During a subsequent coupling step to give 17, the purge 
factor for the starting arylboronic acid 15 was found to be 10 for crystallisation.23 
Scheme 2. Route to MK-8876 
  
1.3 Ordering of the review material 
Published work on impurities in pharmaceutical or related solids broadly cover two 
approaches both of which are represented in this review. The first are cases of occurrence 
and/or removal of impurities in crystallisations and related processes drawn from reports of 
process chemistry and process development. The second are studies on the inclusion of 
impurities in solids, especially in crystal lattices. Many of the latter involve solid solutions. 
These two approaches rarely overlap, hence understanding of how impurities form part of the 
composition of solids obtained by process crystallisations is limited.  
Scheme 3 summarises the common relationships between processes such as reactions and 
crystallisations, the generation of products and impurities, and the removal of the latter. The 
scheme is based on generalisations from the reported literature on impurities in 
pharmaceutical and fine chemical manufacturing over the review period. A number of reports 
of impurity removal in conjunction with a phase transformations were noted. This approach is 
particularly appropriate if the crystal lattice of the initial crystal form is insufficiently 
discriminating in the rejection of impurities. In such cases, a different crystal lattice may be 
more discriminating.  
In line with the trends observed in Scheme 3, the review will cover cases which fall under the 
following general classes. 
 Class I: Impurities which are satisfactorily removed by recrystallisation. 
 Class II: Impurities which are not satisfactorily removed by recrystallisation. 
 Class III: Impurities which are removable in conjunction with a phase transformation. 
In the next section, cases from the literature will be described, sub-divided according to how 
they fall into the above classes. Note that any individual process may display more than one 
class of behaviour, i.e. may have impurities which were acceptably removed by 
crystallisation, (Class I) or were not so removed (Class II), or required a phase transformation 
(Class III). The literature cases studies are therefore presented in the following order: Class I 
behaviour only, Class II behaviour only, Class I and II behaviour, Class III behaviour only, 
Class I and III behaviour, Class II and III behaviour, and Class I, II and III behaviours. 
Information on the cases reviewed is taken as reported and were not evaluated for how 
extensive the process development was for any specific case. 
The review will examine incorporation of impurities within crystal lattices and at crystal 
growth steps. Formation of solid solutions is clearly an important possibility in cases in 
which impurities are not removed by crystallisation, but other modes of inclusion or 
absorption need also be considered, examining factors such as variation on crystal growth and 
morphology, surface adherence and washing efficiency. An overview of the material also 
suggested that particular process types were particular prone to generate of impurities, for 
example alkylation reactions. We, therefore, also examined the correlation between the 
processes for removing impurities and the reactions which generate them. 
Scheme 3 Schematic of general relationships between reaction process, products and 
impurities. 
 
 
 
2. Impurity occurrence in crystallisations in process chemistry 
2.1 Class I only 
In manufacturing scale crystallisations, impurities are often adsorbed on crystal surfaces and 
can be removed by efficient washing. An example is provided by the manufacture of 
bisphenol A 19 by condensation of phenol 18 and acetone,24,25  giving rise to a wide variety 
of impurities, including unreacted phenol 18, 2',4''-dihydroxyl-2,2-diphenylpropane 20, 
isopropenylphenol 21 and many others (Scheme 4).26 One process for the crystallisation of 
bisphenol A gave product which was found to be 99.5% pure, with the main source of 
impurities being mother liquor adhering on crystal surfaces. The temperature stages of the 
crystallisation protocol were altered to reduce the amount of fine crystals and increase the 
average crystal size, allowing for improved separation of crystal product from the mother 
liquor, giving material of 99.8% purity. Further recrystallisation was found to improve the 
quality of the bisphenol A product up to 99.99%.27   
Scheme 4. Production of Bisphenol A 
 
  
 
Methyl tetra-O-acetyl--D-glucopyranuronate 23 has been very widely used as a protected 
intermediate in the synthesis of glucuronides.28-30 Compound 23 is prepared from D-
glucurono-6,3-lactone 22 by reaction with methanol and sodium hydroxide followed by either 
acetic anhydride in pyridine or acetic anhydride with perchloric acid (Scheme 5).31 The 
product is isolated by cooling of the final reaction mixture from which the product 
crystallises. Processing of the mother liquors has provided the -anomer 24, i.e. both the  
and  anomers are formed.32 For example, in one operation of the process, the required -
anomer 23 was obtained as a crystalline solid in 39% yield, while the mother liquor was 
subjected to silica gel chromatography to provide the -anomer 24 as a crystalline solid in 
37% yield. HPLC analysis of batches of the  anomer 23 showed 2.5 to 3.0% of the 
crystallised material to be the  anomer 24. No  anomer 24 was detected in any of the 
recrystallised batches of  anomer 23. Thorough washing of the directly obtained  anomer 
23 with methanol was also found to remove completely the  anomer 24, i.e., impurity 24 
can be removed by efficient washing.33 
Scheme 5. Preparation of Methyl Tetra-O-acetyl-D-glucopyranuronate 
 
 
 
2.2 Class II only 
In the synthesis of birinapant to support clinical trials as a treatment of cancer and HBV, 
removal of carbobenzyloxy groups by hydrogenation was required in the synthesis of 
intermediate 26 (Scheme 6). In addition to the required product 26, the des-fluoro product 27 
was also obtained in 1.0 to 1.5 % quantities. Compound 27 could not be removed by 
recrystallization and was carried though to subsequent steps.34 Use of HBr/HOAc as 
alternative to hydrogenation for removal of the carbobenzyloxy groups avoided the 
problem.34,35 
Scheme 6. Deprotection by Hydrogenation Step in a Route to Birinapant 
 
 During process development for the manufacture of palbociclip, a Heck coupling step to 
obtain the intermediate 29 gave rise to impurities 30, 31, 32 and 33 (Scheme 7). Isolation of 
the required product 29 by addition of water/nBuOH, filtration, addition of 
water/diaminopropane (to scavenge palladium residues), separation of the organic layer, 
seeding, cooling from 60 to 20 °C, and washing of the isolated solid with nBuOH and MTBE 
gave compound 29 with the impurities 30, 31, 32 and 33 present in quantities from 0.1 to 
1.0%.36, 37 Replacement of catalyst and ligand with Pd(OAc)2 and DPEPhos reduced levels of 
all impurities to below 0.05%, except for the des-bromo impurity 30, which was still over 
0.5%. Optimising reaction temperature, catalyst loading, catalyst to ligand ratio and 
controlling water content also minimised impurities. Filtration and washing with aqueous 1,2-
diaminopropane were effective in reducing palladium residues to below 200 ppm.36 
Scheme 7. Coupling Step in a Route to Palbociclip 
  
2.3 Class I and Class II 
Several routes to the antidepressant fluoxetine hydrochloride 35 are known, many of which 
involve 3-methylamino-1-phenylpropanol 34 as an intermediate product (Scheme 8).38,39 This 
can be converted into fluoxetine hydrochloride by reaction with 4-
chloro(trifluoromethyl)benzene. The hydrochloride can be crystallised by addition of 
anhydrous HCl to a solution of the product free base in ethyl acetate, with recrystallisation 
from, for example, acetone, giving typically 80% yield of 35 by cooling crystallisation. 
Several impurities were observed, including unreacted 3-methylamino-1-phenylpropanol 34 
and the N,O-diarylated derivative 36, however, both are reduced to less than 0.1% by the 
recrystallisation step.40  
Scheme 8. 4-Chloro(trifluoromethyl)benzene Route to Fluoxetine.HCl 
  
Other impurities were found in routes to fluoxetine hydrochloride 35 which displayed Class 
II behaviour. For example, many routes to 35 involve a reductive step, using reagents such as 
B2H6, NaBH4, H2/Pd-C, LiAlH4 or Zn/AcOH, giving compound 37 (Figure 4) as an impurity 
formed by removal of the benzylic hydroxyl group.39 Many routes also involve a late stage 
von Braun demethylation using ethyl chloroformate (Scheme 9).41 Under these conditions, a 
chloride side-product 40 can also form, along with N,N-dimethylethylcarbamate, which can 
be subsequently alkylated to give the persistent impurity 41 in up to 3% depending on the 
precise route. For both the de-hydroxylated impurity 37 and impurity 41, recrystallization of 
fluoxetine hydrochloride 35 from acetone can fail to remove up to half of the impurity.40 
 
Figure 4. Reduction Step Impurity from Fluoxetine.HCl Syntheses 
 
Scheme 9. Von Braun Demethylation in Fluoxetine.HCl Synthesis 
  
A hydrogenation step leading to an intermediate 43 in the synthesis of beta-amyloid cleaving 
enzyme inhibitor LY2886721 gave two impurities including a deacetylated derivative 44 
which was adequately rejected by crystallisation from water and 1-propanol (Scheme 10).42 
By contrast, a des-fluoro impurity 45 was less well rejected. It was necessary to supress 
formation of impurity 45 to <0.1% by addition of acid to the process, at the cost of increased 
but manageable quantities of the deacetylated impurity 44.42  
Scheme 10. Synthesis of an Intermediate in a Route to LY2886721 
 
During development of a route to the serotonin receptor antagonist flibanserin, the 
intermediate 47 and impurities 48, 49 and 50 were obtained from an alkylation process 
(Scheme 11). The vinyl impurity 49 and the dimeric impurity 50 were completely removed 
by recrystallisation from heptane. The bromo impurity 48 was not completely removed but 
was consumed in the next step of the process.43 
Scheme 11. Alkylation Step in a Route to Flibanserin 
 
 
Manufacturing of 1-monoolein 52 by enzymatic acylation of glycerol-1,2-acetonide 51, 
followed by hydrolysis using Amberlyst resin in methanol, was found to give a number of 
impurities. Recrystallisation from hexane at −30 °C over 5 hours was sufficient to remove 
methyl oleate, oleic acid and 1-monooleoyl-2,3-acetonide 53 impurities (Scheme 12). 
However, multiple recrystallizations were required to completely remove the 2-monooleate 
54 and glycerol impurities.44 
Scheme 12. Route to 1-Monoolein 
  
Cevimeline 56, a muscarinic receptor antagonist, is obtained by a route with gave a mixture 
of cis and trans isomers, in which the cis isomer 56 is the required API and the trans isomer 
57 constitutes an impurity (Scheme 13).45 Provided the cis isomer 56 is in excess, formation 
of a sulfonate salt gives a solid enriched in the cis isomer 56, from which further formation 
and crystallisation of the hydrochloride salt gives the API in >99.5% purity.46 
Scheme 13. Route to Cevimeline 
 
Trans isomer 57 can be obtained as a reference standard, using the filtrate following 
crystallisation of the cis isomer 56, as the camphorsulfonic acid (CSA) salt 58 (Scheme 14). 
Evaporation to dryness gives a mixture of the isomers as CSA salts, enriched in the trans 
isomer 59. Re-dissolution in MTBE and crystallization of the HCl salt by addition of aq. HCl 
and IPA, followed by recrystallization from acetone, gave the hydrochloride salt 57 
predominantly as the trans isomer (Scheme 14). This sequence reduced the cevimeline 56 
content from ca. 33% to ca. 4%, however preparative HPLC was necessary to obtained fully 
pure trans isomer 57.47 
Scheme 14. Isolation of the Trans Isomer of Cevimeline 
 
 
Phenacetin 61 was marketed as an analgesic and anti-pyretic drug before being withdrawn 
due to nephrotoxicity.48 One preparation of phenacetin involves ethylation of 4-
hydroxyacetamide 60 (i.e. paracetamol or acetaminophen) (Scheme 15).49,50 This process 
gives unreacted 60 and the N-ethylated derivative 62 as impurities in quantities of up to 1%, 
with 62 as the major impurity. Impurity 62 is completed removed by recrystallisation, despite 
being the more abundant impurity, while starting compound 60 may not be completely 
removed after multiple recrystallizations.51 Related substances such as 4-ethyloxyaniline (4-
phenetidine) 63 (Scheme 16), a degradation product of phenacetin, was also found to be 
effectively excluded from phenacetin crystals (Supplementary Information). An amide C4 
hydrogen bonded chain52 is a key feature of the crystal structure of phenacetin.53 As a tertiary 
amide, compound 62 cannot serve as a component of an amide C4 chain, which provides an 
attractive rationale for its poor inclusion into the phenacetin crystals (Scheme 16). As an 
aniline, 4-ethyloxyaniline 63 possess N-H bonds with can donate hydrogen bonds as part of a 
C4 chain, but lacks the carbonyl C=O bonds necessary to accept hydrogen bonds as part of 
such as chain (Scheme 16).  
Scheme 15. Preparation of Phenacetin 
 
 
Scheme 16. Likely Discontinuity of the Phenacetin Amide C4 Chain by 4-Hydroxy-N-
ethylacetanilide 62 and 4-Ethoxyaniline 63 
 
 
 
During development of a kilo-scale synthesis of doravirine 67, des-methyl doravirine 66 
could be obtained by reaction of the pyridone 64 and triazolinone chloride 65 (Scheme 17).54 
Recrystallization from acetonitrile/water give complete rejection of remaining triazolinone 
chloride 65.55 Subsequently methylation of des-methyl doravirine 66 gave doravirine 67. 
After removal of the base by filtration, addition of water gave crude doravirine 67 including 
ca. 5% bis-methyled impurity and impurities methylated at alternative positions. 
Recrystallisation from NMP-ethanol sufficiently removed these impurities. 
Scheme 17. Steps in a Synthesis of Doravirine 
 
 
Synthesis of the cyano intermediate 64 also produced the bis(cyano) impurity 69, which 
could not be adequately removed (Scheme 18). Investigation of THF, acetone, toluene, IPA, 
DMF/H2O, acetonitrile, dioxane, 2-butanone and methanol as solvents for the crystallization 
of intermediate 64 gave 2.0 to 3.6% of impurity 69.54 This was avoided by altering the 
reaction conditions to CuCN in NMP, and use of the iodo analogue of the bromide 68.54,56 
Scheme 18. Synthesis of an Intermediate in a Route to Doravirine 
 
 
 2.4 Class III only 
 
The HSP90 inhibitor 72 (Scheme 19) below was obtained by alkylation at the N9 position of 
chloropurine 70 followed by isolation of the mesylate salt. The main impurity observed was 
the N7 alkylated isomer 73 which was found as a 1.4% impurity in the crude material. 
Crystallisation of the mesylate salt of 72 from DMSO by antisolvent addition also resulted in 
some formation of a hydrolysis product 74 in quantities of up to 0.4%. Use of methyl acetate 
as the anti-solvent gave material containing 0.45% of the N7 alkylated impurity 73, while use 
of ethyl acetate as antisolvent gave 0.28% of the same impurity. In the final developed 
process, the methylate salt 72 was dissolved in DMSO at 22 °C, ethyl acetate antisolvent was 
added with seeding and cooling to 0 °C to give the required product with both impurities 
under 0.06%.57 
Scheme 19. Route to HSP90 Inhibitor 
 
 
Three polymorphs of an unidentified ‘API X’ 75 (Figure 5) were known, designated forms A, 
B and C, of which the crystal structures and supramolecular packing motifs of these forms 
were fully characterised. A dimer 76 involving H∙∙∙F hydrogen bonds was one of the motifs 
found in forms A and B. Compounds 77, 78, 79 and 80 had been found as process impurities 
and the impact of these on crystallisation of 75 was investigated. For example, it was found 
that impurities 77 and 78 inhibited the transformation of form A to form B at 30 ºC in IPA.  
Under these conditions, form B is the thermodynamically preferred form and batches of pure 
form A, or form A in the presence of impurities 79 or 80, transform to form B.  It was noted 
that impurities 77 and 78 possess the molecular groups necessary for formation of a dimer 
motif similar to 76, whereas impurities 79 and 80 lack such groups. Impurities 79 or 80 can 
therefore mimic dimers 76 and affect the polymorphic transformation.13 
 
Figure 5. API 'X' and Impurities 
 
2.5 Class I and Class III 
In development of a manufacturing route to axinitib, a telescoped process was used to obtain 
the intermediate 83 (Scheme 20). Recrystallisation was necessary to control impurities 84, 85 
and 86, present in quantities of 0.1% to > 2.0% in the crude material. Dissolution in NMP, 
with 1,2-diaminopropane to solubilize palladium residues, followed by addition of methanol, 
followed by water antisolvent, give the following acceptable levels of impurities 84, 85 and 
86 in quantities of 0.05% to 0.80%.58 
Scheme 20. Synthesis of an Intermediate in a Route to Axinitib 
 
 
Axinitib 87 itself (Figure 6) was found to be highly polymorphic with at least five anhydrous 
forms and many solvates. Compound 87 was obtained from a Heck coupling in NMP, after 
which the reaction mixture was diluted with THF containing 1,2-diaminopropane to 
solubilize palladium residues. The crude product was isolated as a THF solvate by cooling 
and water antisolvent addition. Recrystallization from NMP/THF with ethanol antisolvent 
addition, seeding and slow cooling gave axitinib 87 as the preferred anhydrous polymorph. 
The impurities found were compound 84 (0.21 – 0.30% in crude material), 88 (0.13 – 0.17% 
in crude) and 89 (0.11 – 0.13% in crude). After crystallisation as described, these were all 
reduced to ≤0.05% and palladium levels below 7 ppm.58  
 
Figure 6. Axitinib and Impurities 
 
In the development of a route to an oxazolidinone intermediate, a Mitsunobu coupling step 
was used to form both isoxazole and oxazolidone products, which, following debenzylation 
and hydrochloride formation gave 91 and 92 respectively, the latter as an impurity in up to 
4.5% quantities (Scheme 21). Two crystal forms of oxazolidinone 91 were observed, a 
hydrate which occurred as needles and an anhydrous form which occurred in a morphology 
described as "lumps". It was found that the hydrate form displayed very good selectivity for 
rejection of impurity 92, whereas the anhydrous form showed poor rejection, accommodating 
up to 4% of the impurity. Determination of the crystal structures of both forms showed that a 
key motif in the structure of the anhydrous form was a  interaction involving the central 
difluoroaryl and oxazolidinone rings of 91, but not the terminal isoxazole and piperidine 
rings, which was consequently not discriminatory towards the isoxazolidinone ring of 92. By 
contrast, the structure of the hydrate contained a hydrogen bond between the water molecule 
and the ring oxygen of the isoxazole, which cannot be formed by impurity 92. Hence, 
ensuring that 91 crystallised as the hydrate form gave material with quantities of impurity 92 
in acceptable levels of ≤0.3%.59 
Scheme 21. Synthesis of an Oxazolidinone Intermediate 
 
 
2.6 Class II and Class III 
During the process development for the manufacturing of S-2367 93, a neuropeptide Y 
receptor antagonist, an acid impurity 94 was found to be above specification (> 0.06%) in a 
pilot plant process (Figure 7). Studies on the recrystallisation of S-2367 93 from aqueous 
acetone indicated that the acid 94 was forming as a hydrolysis degradation product during 
recrystallisation. Residual HCl in the batches for recrystallisation, arising from use of thionyl 
chloride in a previous step, promoted the hydrolysis of the amide group in 93. Use of dry 
acetone gave poor throughput of material. Washing was found to be ineffective at removing 
the residual 94, hence it was concluded that compound 94 was enclosed in the crystals of 
product 93, possibly by the formation of an intermolecular interaction between the acidic 
impurity 94 and the basic pyridine ring of S-2367 93, i.e. structure 95 in Figure 7. Repeated 
recrystallization was found to give further hydrolysis of 93. It was noted that crude 93 was 
obtained as a metastable polymorph and that this could be converted to the stable polymorph 
by slurrying in aqueous acetone at 55 °C. This was also found to be a mild and effective way 
to remove impurity 94. For this removal to be successful, it was necessary to maintain the 
crude product as the metastable form before slurrying, which was achieved by washing with 
water. However, it was also desirable to eliminate the need for the polymorphic 
transformation, hence it was found that 93 could be obtained as a stable polymorph within the 
specified purity directly by crystallisation provided the acid 94 was converted into its sodium 
salt.60 
 
Figure 7. S-2367 and Degradation Impurity 
 
During the process development of TRVP1 Antagonist 96, the intermediate step shown 
involved crystallization of the product 99 from MTBE/heptane, from which the product was 
found to contain ca. 1.5 mol% of the palladium complex 100. However, the presence of 
complex 100 proved beneficial in a subsequent step. The final product was found to contain 
the impurity 101 in 3% quantity carried through from previous steps in which it had not been 
rejected by crystallization by salt formation (Scheme 22).61 However, target compound 96 
was also found to form a crystalline DMSO solvate which rejected impurity 101. Hence, the 
aqueous reaction extract (after washing to remove other impurities) was extracted into MTBE 
and the solvent switched to DMSO, which resulted in a slurry of the DMSO solvate with 
stirring at room temperature. The solvate was isolated, dissolved in DMAc/water, aq. NaOH 
added and warmed to 45 °C to achieve dissolution, MsOH was added and cooled to 
crystallize the mesylate salt of 96 without impurity 101.61 
Scheme 22. Intermediate in the Synthesis of a TRVP1 Antagonist 
 
 
2.7 Class I, Class II and Class III 
The case of (R,R)-formoterol tartrate (104, Scheme 23) provides an example of the inter-
action between process chemistry, impurities and crystallisation outcomes.  The final step in 
the synthesis of this compound was salt formation, which also resulted in the precipitation of 
a crystalline product in which compounds 105, 106, 107 and 108 were identified as 
impurities.10, 62-64 Three crystal forms of (R,R)-formoterol tartrate 104 were identified, 
polymorphic forms A and B and a hydrate (form C). The initially precipitated material was 
form B and contained all four impurities in quantities of 0.04% to 0.64%, above the specified 
levels. Recrystallisation of the precipitated material from 25% aq. IPA gave crystals of form 
A, the thermodynamically preferred form, in which impurities 105 and 106 were no longer 
detectible, impurity 108 was reduced by 50%, but the levels of impurity 107 were increased 
due to further formamide degradation. Alternatively, warming the initially slurry of 
compound 104 resulted in significant re-dissolution of all four impurities, and formation of 
hydrate form C.  Combination of re-slurrying and recrystallisation also gave low levels of all 
four impurities and solid material as the preferred crystal form A.10 
Scheme 23. Route to (R,R)-Formoterol Tartrate 
  
3. Incorporation of impurities within crystal lattices and faces 
Section 2 presents examples of impurities occurring in process chemistry in terms of the 
behaviour of the impurities as they undergo crystallisation or related operations. Generally in 
such cases the purity or composition of batches is measured by standard sampling and 
analytical methods, most often by HPLC. One issue not addressed by such an approach is 
determination of the locations at which particular impurities are present and how the 
impurities can exist as components of the material at those locations. This issue has been 
studied, but in general separately from the management of impurities in process chemistry. 
However, to develop rational approaches to impurity management, better understanding of 
the modes of incorporation of impurities into crystalline solids is required. Hence, relevant 
work in that area is also examined, although most cases are not arising as a consequence of 
processes which would be typical of 'process chemistry'. The cases selected for this section 
are 'drug-like' small organic molecules, and so the examples may be instructive when 
considering typically more complex API-like molecules such as those covered in Section 2.  
Relatively few studies have investigated the location and supramolecular inclusion of 
exogenous molecules such as impurities within molecular crystals. One example concerns the 
crystallization of L-asparagine monohydrate (109, Figure 8) from water. Other amino acids 
present as impurities in solution can be incorporated into L-asparagine monohydrate crystals 
but to differing extents and distributions. Careful sequential dissolution and analysis studies 
on individual L-asparagine monohydrate crystals showed that most amino acid impurities 
were largely located on the outer or surface layers of the crystals. However, L-aspartic acid 
110 was found to be incorporated into L-asparagine monohydrate crystals in significant 
quantities (>10%) and to be distributed relatively uniformly throughout the crystal, indicating 
a possible systematic substitution of L-aspartic acid molecules for L-asparagine molecules 
within the L-asparagine monohydrate crystals.65 This possibility was examined by neutron 
diffraction studies of deuterated L-asparagine monohydrate crystals grown in the presence of 
deuterated aspartic acid, which showed a reduction in symmetry from P212121 for L-
asparagine monohydrate crystals to P21 for crystals grown with aspartic acid impurity, due to 
systematic substitution of aspartic acids molecules for aspargine molecules in the crystal 
lattice.66 
 
Figure 8. L-Asparagine and L-Aspartic Acid 
 
The effects of L-leucine 6 (Figure 9) impurities on the phase and morphology of L-isoleucine 
5 crystals, with impurity levels ranging between 0.01 and 0.1 ratio of moles 6 to moles of 5 
has been examined. A significant reduction of crystal size was observed at 0.01-0.03 ratio but 
further amounts had little further effect. Impurity 6 also had an effect on the aspect ratio of 
the crystals. A single crystal XRD analysis was carried out on a larger crystal contaminated 
with 6 in ratio of 0.13, showing some distortion of the unit cell dimensions relative to that of 
pure 5. It was possible to simulate substitution of molecules of 5 by molecules of 6 at lattice 
sites by modelling.19 
 
Figure 9. L-Isoleucine, L-Leucine, L-Valine, L-Norleucine and L-Homoleucine 
 
A further study of the crystallisation of L-isoleucine 5 in the presence of related amino acids, 
found incorporation of L-valine 7, L-leucine 6, L-norleucine 111 and L-homoleucine 112 
(Figure 9) in a range of 0-5% depending on amount of the impurity present in the 
crystallising solution. Most were in the range 0-2% with only L-leucine 6 greater than 2%. It 
was found the increasing incorporation of L-norleucine 111 corresponded to lengthening of 
the c axis of the unit cell of L-isoleucine 5 to accommodate the longer side chain of L-
norleucine 111.67 
During crystallization of the phosphoantigen C-HDMAPP 113 (Figure 10) containing the 
impurity 114, a significant proportion of impurity 114 remained in crystals of 113 after 
recrystallization. For example, crystallization of 113 from a solution containing 5.6 wt% of 
impurity 114 gave crystals consisting of 2.47 wt% of 114. However, the extent of impurity 
114 decreased to very low levels with slurrying of the material in water-ethanol, suggesting 
(with other findings) that the impure material existed as a metastable solid solution favoured 
by fast crystallization kinetics. Replacement of one 113 anion per unit cell with the 114 anion 
was modelled and was found to create a significant free volume in the crystal packing and 
loss of a key H-bond in the structure, consistent with the metastability.68 
 
Figure 10. Phosphoantigen C-HDMAPP and Impurity 
 
"Dutch Resolutions" involve the use of families of structurally related resolving agents, as 
against just one such agent in a classical resolution, providing a higher chance of success than 
the classical approach.69,70 Studies on the mechanism of these resolutions suggested that a 
degree of incorporation of a salt of one of the resolving agents other than principal one may 
be involved, although kinetic effects may also be significant. For example, the related salts 
115 and 116 (Figure 11) were found to form a full solid solution when simulated by 
modelling.71 
 
Figure 11. INAM and CLINAM 
 
9,10-Dichloroanthracene 117 and 9,10-dibromoanthracene 118 (Figure 12) were used in a 
study on the crystallization and phases produced from isosteric molecules. When crystallizing 
from solutions containing 1:4 to 1:6 ratios of 117 to 118, a phase similar in lattice constants 
and molecular arrangement to the known structure for 118 was obtained, but having smaller 
unit cell volumes, consistent with incorporation of 117. When crystallizing from solutions of 
117 containing 1 mol% 118, solid 118 was obtained, but also some thin needles which were 
found to be a solid solution with a very low content of 118, ca. 3% based on occupancy 
refinements, in crystals of 117.72 
 
Figure 12. 9,10-Dichloroanthracene and 9,10-Dibromoanthracene 
 
Crystallisation of acetaminophen (paracetamol) 60 by supercritical-CO2 crystallization in the 
presence of p-acetoxyacetanilide 119 (Figure 13) impurity has been studied. Uptake of 119 
was found to depend on the crystallization kinetics as well as the concentration of 119 in 
solution. The presence of impurity 119 affected the morphology of particles of 60, giving 
more elongated prisms. The precipitated solid was analysed by selective dissolution, which 
found that 60 and 119 molecules formed a homogenous solid solution. XRD analysis 
indicated that incorporation of molecules of 119 into the crystal lattice of 60 caused 
systematic shifting of diffraction peaks to smaller angles, i.e. increased d-spacing. Peak 
spreading was found to be consistent with expansion in the b crystallographic direction to 
accommodate the longer molecules of 119 within the crystal lattice of 60.73 
 Figure 13. Acetaminophen (Paracetamol) and p-Acetoxyacetanilide 
 
In one preparation of phenacetin 61, the starting material, 4-hydroxyacetamide 
(acetaminophen or paracetamol) 60, was not completely removed after multiple 
recrystallizations (see Section 2.3). A stepwise dissolution study of individual phenacetin 
crystals found that compound 60 could be detected even in the final dissolution of the 
phenacetin particles. This finding could be rationalised by examination of the crystal 
structures of phenacetin, which contains a continuous amide hydrogen bonding chain, into 
which molecules of 60, also a secondary amide, could be accommodated (Figure 14).51 A 
study on the inclusion of other related secondary amides such as acetanilide 120 and 4-
methoxyacetamide 121 found that these were also incorporated into the interiors of 
phenacetin crystals and could not be removed by washing. While concentrations of 60 and 
120 were greatest near the surface of the crystals, the distribution of 4-methoxyacetanilde 121 
was found to be uniform throughout the phenacetin crystals, in a proportion dependent on its 
concentration in solution (Figure 15 and Supplementary Information). These data show that 
impurities 60, 120 and 121 can be accommodated within the interior bulk of the phenacetin 
crystals, significantly contributing to the difficulty of removing them. Analysis of impurity 
incorporation in this manner provides a direct evaluation of the challenge is removing a 
particular impurity by recrystallisation, as against an evaluation of the general potential for 
removal of an impurity that would be provided by determination of a purge factor (Section 
1.2). 
 Figure 14. Participation by Secondary Amide in the C4 Chain of Phenacetin 
 
 
Figure 15. Relative quantities (percentage area by HPLC) of impurity compounds 120 (left 
column in dark grey) and 121 (right columns in light grey) incorporated into crystals of 
phenacetin 61 grown from solutions containing 5 mol% impurity determined at three 
successive dissolution stages (Supplementary Information). 
 
Formation of partial solid solutions is observed in the crystallisation of enantiomers of malic 
acid, 122 and 123 (Figure 16). A detailed study of the crystal phases and corresponding phase 
diagrams for this system found, inter alia, stable and smetastable forms of the racemic 
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compound. These could occur as mixed crystals containing racemate and additional single 
enantiomer, for example, the stable racemic compound could occur with up to 70% of one 
enantiomer, i.e.as a partial solid solution. This observation could be rationalised on a crystal 
structural basis in that the racemic compound contains hydrogen bonded chains linking 
alternating R and S acids as 'head to head' and 'tail to tail' dimers in an alternating -R-S-R-S- 
sequence (Figure 17). The structure of the single S enantiomer likewise contains chains 
featuring 'head to head' and 'tail to tail' dimers, but in an –S-S-S-S- sequence (Figure 18). 
Partial solid solution formation is possible if, for example, an –R-S-S-S-R- sequence could be 
accommodated in the structure of the racemic compound.74 
 
Figure 16. Enantiomers of Malic Acid 
 
 
Figure 17. Molecular structure of the dicarboxylic acid chain of the stable (R,S)-malic acid 
(heterochiral R-S-R-S; “head-head”, “tail-tail”). Reprinted with permission from Kaemmerer, 
H.; Lorenz, H.; Black, S. N.; Seidel-Morgenstern, A. Cryst. Growth Des. 2009, 9, 1851-
1862.Copyright 2009 American Chemical Society. 
 
 
Figure 18. Molecular structure of the dicarboxylic acid chain of (S)-malic acid, (homochiral 
S−S−S−S; head-head; tail-tail). Reprinted with permission from Kaemmerer, H.; Lorenz, H.; 
Black, S. N.; Seidel-Morgenstern, A. Cryst. Growth Des. 2009, 9, 1851-1862.Copyright 2009 
American Chemical Society. 
 
Eutectic formation provides another mode of inclusion of extraneous molecules in solid 
materials. For example, in the presence of fumaric or succinic acids, ethambutol 
dihydrochloride 124 (Figure 19) forms hygroscopic eutectics in which the microstructures of 
the resulting solids feature phase separated lattice domains matching those of the individual 
components.75 
 
Figure 19. Ethambutol Dihydrochloride 
 
During a study of the crystal growth mechanisms of [Cu(bpp)3Cl2].2H2O coordination 
polymer by in situ AFM, it was found that ligand purity was an important factor. 
Commercially supplied bpp ligand 125 (Figure 20) was found to contain unknown impurities 
in up to 5% quantities. When this material was used, AFM showed the presence of bunched 
steps not seen when pure ligand 125 was used (Figure 21). Impurities were strongly absorbed 
at terraces and steps forced to grown around these, such that the steps cannot stay straight and 
become bunched.76  
 Figure 20. Structure of Ligand 'bpp' 
 
 
Figure 21. (A-D) AFM growth sequence (images a-c 10.9 x 10.9 μm2, image d 15 x 15 μm2, 
28 s interval) of a (001) face in the presence of unknown impurities at supersaturation 
β=1.05. (e) Scheme of the Cabrera-Vermilyea model for adsorption of impurities at terraces. 
Mean separation of impurities relative to their critical radius is dimp. Reprinted with 
permission from Moret, M.; Rizzato, S. Cryst. Growth Des. 2009, 9, 5035-5042. Copyright 
2009 American Chemical Society. 
 
4.  Conclusions 
In reviewing the behaviour and fate of impurities generated during process chemistry when 
undergoing crystallizations and related processes such as slurrying, a number of distinct types 
of behaviour were noticeable. Many impurities are satisfactorily removed by washing, 
recrystallization or reslurrying, i.e. Class I behaviour. However, some impurities are not 
adequately removed by these processes, in which case adjustment of the reaction or 
extraction steps may be necessary, i.e. Class 2 cases. Crystal phase transformations often 
provide good opportunities for impurity removal, Class 3, although the presence of impurities 
constitutes a challenging variable in crystal phase control. 
An important question that arises in cases in which impurities are not satisfactorily removed 
by washing, recrystallization or reslurrying concerns the nature of the incorporation of the 
impurities into the crystalline material. This particular issue has not been widely studied in a 
process chemistry context. However, incorporation of extraneous molecules into crystal 
lattices has been well investigated and in many cases has been associated with formation of 
solid solutions. Surface inclusion of impurities has also been observed as well as eutectic 
formation and formation of physically separate solids. 
The cases reviewed were examined for any correlation between impurity type (e.g. functional 
group, molecular system, reaction by which the impurity was formed) and observed 
behaviour. The following categories were identified as the most common discernible impurity 
types:  
 Starting materials 
 Isomers or analogues: stereoisomers, regioisomers, homologues or analogues 
 Alkylation impurities, i.e. from incomplete alkylation, overalkylation or alkylation at 
alternate sites 
 Impurities formed by dehalogenation (replacement with hydrogen) or other reduction 
process. 
 Impurities formed by hydrolyses or the reverse 
 Oxidation products, elimination products or products of other completing processes 
 Palladium or other metal residues or complexes 
Table 1 shows how these impurity types map to the Classes I, II and III. This is a qualitative 
approach and is only as representative as the cases reviewed above. The findings in Table 1 
suggest that isomers and analogous compounds can have good capacity for incorporation into 
lattices, so may be difficult to remove by crystallisation or related processes, although in a 
minority of cases are quite easily removed. Residual starting materials and alkylation 
impurities are often removable by recrystallisation or in conjunction with a phase 
transformation. Dehalogenated compounds and reduced or hydrogenated impurities can have 
good capacity for incorporation into lattices, so may not be always easily removable but may 
have good potential for removal in conjunction with phase transformation. The structural 
similarity between any impurity and the crystallising compound will clearly be one of the 
factors determining its class of behaviour, however, several other factors will be significant. 
In particular the relative solubility of any impurity in comparison to the crystallisation 
compounds in the crystallisation medium is another factor which will be very significant. As 
solubility is strongly structure dependent, these two factors are closely linked. 
 
Table 1. Number of instances of each category of impurities occurring in each Class of 
behaviour. 
 Class 1 Class 2 Class 3 
Starting materials and reagents 5 1 4 
Isomers and analogues 6 12 0 
Alkylation impurities 4 1 3 
Dehalogenations or reductions 1 3 4 
Hydrolyses or the reverse 3 3 4 
Oxidations, eliminations or other 
processes 
5 5 1 
Metal residues or complexes 3 1 0 
 
The issue of how and how well impurities are included in crystalline products is complex. 
Impurities which can reasonably replace crystallising compounds as points in the crystal 
lattice have the most obvious potential for incorporation, for example by forming solid 
solutions. Such impurities should have clear structural similarity to the crystallising 
compounds, be capable of fulfilling all the essential supramolecular interactions of the 
crystallising compounds and not possess any sterically or electronically lattice-distorting 
features. Several examples are given in Section 3. However, solid solutions are not the only 
mode of incorporation of impurities. Likely to be as important are incorporation modes which 
cannot be rationalised in term of crystal structures and which may be highly dependent on 
issues such as the degree of crystallinity, crystal mosaic spread, surface roughness, defects, 
solution supersaturation, the kinetics of the crystal growth process, the mode of isolation, e.g. 
by filtration, and the efficiency of washing of the isolated solids. 
Achieving a better understanding of the inclusion of such impurities requires improved 
determination of the locations of impurities within crystalline samples linked with an 
understanding that these may be not be uniformly distributed. XRD methods can be used to 
detect distortions in unit cell dimension as a consequence of solid solution formation or 
inclusion of impurity molecules within crystal lattices. PXRD diffraction peak shifts, 
observation of changes in axis lengths, occupancy refinement and symmetry changes detected 
by neutron diffraction have been utilised for this purpose. Modelling of substitution of 
impurities within lattices can be used to evaluate the effect on lattice stability and the 
potential for inclusion. Microscopy techniques such as SEM and AFM observe changes in 
crystal growth phenomena arising from impurity inclusion at surfaces. Eutectic formation can 
be difficult to observe as XRD and spectroscopic methods are relatively insensitive toward 
eutectic structure. Depression of melting point determined by DSC, HSM or other thermal 
methods, especially when part of rigorous determination of phase diagrams, is more 
appropriate for the detection of eutectic formation. Sequential dissolution and analysis studies 
can determine occurrence of impurities at outer surface layers of crystals or distributed within 
crystal interiors. 
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SUPPLEMENTARY INFORMATION 
Data on the incorporation into phenacetin 61 crystals of 4-phenetidine 63, acetanilide 
120 and 4-methoxyacetanilide 121 
 
 
 
Crystal growth Compounds and solvents were purchased from Sigma-Aldrich. Phenacetin (50 
mg) and one of each impurity were mixed to give samples containing each impurity as either 
5%, 10% or 15% of the total number of moles of each sample. These samples were dissolved 
in methanol (1.5 mL) with heating to 35 °C to ensure dissolution in all cases. The solutions 
were allow to cool and partially (but not fully) evaporated in semi-covered (partially 
perforated) vials to allow growth of crystals of at least 0.5 × 0.5 × 0.2 mm dimensions. The 
crystals were isolated, washed with 0.4 mL of cold methanol, dried under vacuum and weighed.  
Crystal dissolution For each impurity and concentration, individual crystals were subjected to 
a series of three partial dissolutions followed by analysis of the resulting solutions at each stage. 
The mass of the crystals determined the volumes of solvent used for complete dissolution, to 
give a concentration of 1.0 mg/mL, e.g. 6.0 mL was used for the complete dissolution of a 
crystal weighing 6.0 mg, with. 2.0 mL used for each of the three partial dissolution stages. At 
the beginning of the series of dissolutions, the crystal was placed in a sample vial. The correct 
volume of solvent was added and the crystal was observed partially dissolving. It was then 
removed and washed with a small quantity of cold hexane before being placed in a second 
sample vial to be further dissolved. This process was repeated for a third final stage giving 
complete dissolution. The solutions remaining in the sample vials were analysed by HPLC. 
Each of these experiments was repeated three times. 
HPLC HPLC analysis on the products was conducted on an Agilent 1200 series HPLC, with a 
YMC-Pack ODSA column (250 x 4.6 mm, 5 μm). An isocratic 60:40 MeOH:H2O solvent 
system was employed, at a flow rate of 1 mL/min and an injection volume of 10 μL. The 
detector was set at 254 nm and the oven temperature was ambient.  
 
Table S1 Relative quantities (percentage area by HPLC) of impurity compounds 63, 120 and 
121 incorporated into crystals of phenacetin 61 determined at three successive dissolution 
stages. 
Impurity Mol % 
impurity in 
solution 
% impurity in 
1st dissolution 
layer 
% impurity in 
2nd dissolution 
layer 
% impurity in 
3rd dissolution 
layer 
63 5, 10 or 15 <LOQa <LOQa <LOQa 
120 5 1.61 ± 0.01 0.31 ± 0.04 0.20 ± 0.01 
120 10 2.28 ± 0.02 0.56 ± 0.02 0.45 ± 0.01 
120 15 5.89 ± 0.03 1.44 ± 0.02 0.49 ± 0.03 
121 5 2.88 ± 0.02 2.58 ± 0.01 2.53 ± 0.02 
121 10 6.11 ± 0.01 5.23 ± 0.02 4.97 ± 0.01 
121 15 7.64 ± 0.02 7.36 ± 0.04 6.52 ± 0.03 
a 3.5 x 10-3 mg/mL  
 
 
 
 
